Tonix Pharmaceuticals Added to Russell 3000 and Russell 2000 Indexes

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has been added to the Russell 3000® and Russell 2000® Indexes, a move that underscores the company's growing market capitalization and its progress toward potential FDA approval for TNX-102 SL, its treatment for fibromyalgia. This inclusion is effective as of June 30, following the 2025 Russell indexes reconstitution. The Russell indexes are pivotal benchmarks, with over $10.6 trillion in assets linked to their performance, making Tonix's addition a notable achievement that could enhance its visibility among investors.

CEO Seth Lederman highlighted the significance of this milestone for Tonix as it moves closer to commercializing TNX-102 SL, which has shown promise in two statistically significant phase 3 studies for fibromyalgia management. The FDA has already granted Fast Track designation to TNX-102 SL, recognizing its potential to address an unmet medical need. Beyond fibromyalgia, Tonix is exploring the application of TNX-102 SL for acute stress reaction and is engaged in developing other innovative therapies, including TNX-4200, a broad-spectrum antiviral agent, under a contract with the U.S. Department of Defense.

Tonix's inclusion in these widely followed indexes not only reflects its financial growth but also positions the company for increased scrutiny and investment as it navigates the critical phases of drug approval and market entry. For more details on Tonix Pharmaceuticals and its developments, visit https://ibn.fm/KCfwJ.